A detailed history of Optimum Investment Advisors transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Optimum Investment Advisors holds 50 shares of NTLA stock, worth $434. This represents 0.0% of its overall portfolio holdings.

Number of Shares
50
Holding current value
$434
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 20, 2025

BUY
$9.88 - $17.76 $494 - $888
50 New
50 $0
Q4 2019

Jan 22, 2020

SELL
$10.43 - $17.67 $3,129 - $5,301
-300 Closed
0 $0
Q3 2019

Oct 17, 2019

SELL
$13.07 - $18.51 $13,070 - $18,510
-1,000 Reduced 76.92%
300 $4,000
Q4 2018

Feb 04, 2019

SELL
$11.39 - $27.13 $5,695 - $13,565
-500 Reduced 27.78%
1,300 $18,000
Q3 2018

Oct 05, 2018

SELL
$25.78 - $32.6 $2,578 - $3,260
-100 Reduced 5.26%
1,800 $52,000
Q1 2018

May 09, 2018

BUY
$19.43 - $34.95 $36,917 - $66,405
1,900 New
1,900 $40,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $661M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Optimum Investment Advisors Portfolio

Follow Optimum Investment Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Optimum Investment Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Optimum Investment Advisors with notifications on news.